Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Indonesia Energy Corporation Limited (INDO) Price & Performance

ADMA Biologics IncTrade
Indonesia Energy Corporation LimitedTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Indonesia Energy Corporation Limited — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Indonesia Energy Corporation Limited trades at $2.92 (market cap $44.93M). The key difference: ADMA Biologics Inc is far larger — about 48.5× Indonesia Energy Corporation Limited's market cap. Which is the better fit depends on your goals.

ADMAINDO
Market Cap
$2.18B$44.93M
Sector
HealthEnergy
52-Week High
$20.38$6.74
52-Week Low
$7.60$2.49
Enterprise Value
$2.25B$40.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Indonesia Energy Corporation Limited

INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Indonesia Energy Corporation Limited

Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.

Read more on INDO